ABOS

Acumen Pharmaceuticals, Inc. (ABOS) | Rumor.io

Acumen Pharmaceuticals

ABOS

Attention (50-day avg)0%

Attention rank (50-day avg)#2,858

Bullish sentiment (50-day avg)100%

Price to earnings ratio-1.15

Market capitalization166.3M

Earnings per share-1.64

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-121.3M

Social

What share of all stock conversation is about ABOS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Mar 16

Acumen Pharmaceuticals, Inc. (ABOS) announced a $35.75 million private placement to advance its potential best-in-class molecules from the Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio.
The private placement was led by existing investor RA Capital Management, with participation from other investors, including ADAR1 Capital Management, Sands Capital, and a large investment management firm.
The company expects to receive gross proceeds from the offering of approximately $35.75 million, before deducting offering expenses, and plans to close the private placement on or about March 16, 2026.

Generated by AI

Sentiment

Of the messages about ABOS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	96.85% +10.71
Bearish	—	—	0% 0	3.15% -10.71

Bullish· Jan 27

$ABOS has tremendous potential for growth, backed by big Pharma and successful drug development, which could lead to a significant stock price increase.
A BTIG analyst has upgraded the price target to $7 with a potential upside of 236.54%, indicating a strong buy recommendation.
The stock has seen a 23% intraday surge following a price target hike to $7, suggesting a strong market reaction to positive news.

Bearish· Jul 19

$ABOS's price may drop below its 200-day moving average of $5.65, potentially exacerbated by dilution.
Market makers are allegedly artificially inflating the stock price, as there are no real buyers at the current level of $7.25.
The company's lack of revenue and single-pipeline product make it a high-risk investment, with some analysts predicting a price drop to under $5 in the near future.

Generated by AI

Topics

Of the messages about ABOS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	88.61%
Analysts	—	—	0%	3.16%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	8.23%

Analysts· Jul 26

Credit Suisse initiated coverage on Acumen Pharmaceuticals ($ABOS) with an Outperform rating and a price target of $26.
BofA Securities initiated coverage on Acumen Pharmaceuticals ($ABOS) with a Neutral rating and a price target of $20.
UBS initiated coverage on Acumen Pharmaceuticals ($ABOS) with a Buy rating and a price target of $27.

Announcements· Jul 17

Acumen Pharmaceuticals ($ABOS) announced positive topline results for its early Alzheimer's disease treatment, ACU193, in a Phase 1 clinical trial.
The company plans to hold a conference call to discuss the results and has proposed a public offering of common stock to raise $100 million.
The treatment, ACU193, met its primary endpoint in the Phase 1 trial, showing a significant decrease in amyloid plaque load, and several top Wall Street analysts have upgraded their rating to strong buy.

Technical Analysis· Sep 28

A technical analysis of $ABOS indicates a negative divergence on the chart, with higher highs and lower lows, suggesting a sign to exit the trade and take profit.
The stock's support levels are near $6.54, $7.19, and $7.83, while resistance levels are near $8.63, $9.11, and $9.69, with bulls still in control.
A potential breakout is indicated if $ABOS breaks above $9.50 with strength in the next 5-10 minutes, with a possible target of $11-12.

Generated by AI

Community

Of the messages about ABOS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	80.43%	36.94%
Newcomers	0%	0%	19.57%	63.06%

Regulars· Jul 17

Acumen Pharmaceuticals announced positive topline results from a Phase 1 study of ACU193 for early Alzheimer's disease, with a "rapid" mean decrease in amyloid plaque load at 60 milligrams.
The company's shares climbed more than 37% in premarket trading, with some analysts noting a "nice ride" despite early data being low.
Acumen Pharmaceuticals will hold a conference call to discuss the positive results from the Phase 1 study, with details expected to be shared during the call.

Newcomers· Jan 27

The newcomer is excited about the rapid increase in Acumen Pharmaceuticals' stock price, which rose 52% yesterday, but is unsure of the reason behind it, as the company is set to announce 2nd stage results for its Alzheimer's treatment ACU193 on December 26th.
The newcomer is comparing Acumen Pharmaceuticals to Mindwalk, a biotech company that developed a rapid prime immunization method and its underlying antibodies, and is speculating on the potential success of Mindwalk's 2nd stage results.
The newcomer is tracking the stock price of Acumen Pharmaceuticals, which rose 20% after-hours, and is attributing the spike to flow/volatility-driven momentum, without any clear fresh PR headline attached.

Generated by AI

News

Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery

CRYSTAL LAKE, Ill., September 14, 2026--Aptar and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery

15d agoYahoo Finance

Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?

Here is how Acumen Pharmaceuticals, Inc. (ABOS) and Amarin (AMRN) have performed compared to their sector so far this year.

2mo agoYahoo! Finance Canada

All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy

Acumen Pharmaceuticals (ABOS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

2mo agoYahoo Finance

Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer’s Association International Conference

NEW YORK, NY; NEW HAVEN, CT; and PRINCETON, NJ, July 08, 2026 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM) ("Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company dedicated to addressing unmet medical needs, and DiamiR Biosciences (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and other diseases, today announced upcoming presentations at the annual Alzheimer’s Association International Conference (AAIC), taking place at the Excel

2mo agoYahoo Finance

Also Discussed

Investors talking about ABOS also mention

#	Name	Attention
1	Prothena Corp PLCPRTA	0%0
2	LVTX - LAVA Therapeutics N.V.	——
3	Amylyx Pharmaceuticals, Inc.AMLX	0%+0
4	ICVX - Icosavax, Inc.	——
5	CPTN - Cepton, Inc.	——
6	Vaxcyte Inc.PCVX	0%0
7	PepGen Inc.PEPG	0%new
8	DICE - DICE Therapeutics, Inc.	——
9	INZY - Inozyme Pharma, Inc.	——
10	Connect Biopharma Holdings LimitedCNTB	0%+0

Acumen Pharmaceuticals, Inc.

Healthcare
Biotechnology

Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer’s disease. The company’s lead program centers on sabirnetug (ACU193), an investigational immunotherapy designed to selectively target toxic soluble amyloid beta oligomers, which are believed to contribute to Alzheimer’s pathology. Acumen’s work is aimed at disease-modifying treatment approaches rather than symptom management, with its research and clinical programs concentrated on early symptomatic and mild Alzheimer’s disease. Headquartered in Newton, Massachusetts, Acumen Pharmaceuticals operates within the neuroscience and biotechnology sectors, where it plays a specialized role in advancing antibody-based therapies and diagnostics for neurodegenerative disease.

Website

Location

1210-1220 Washington St.

Newton, MA, 02465

United States

Social

What share of all stock conversation is about ABOS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% 0	0% 0	0% 0

Mar 16

Acumen Pharmaceuticals, Inc. (ABOS) announced a $35.75 million private placement to advance its potential best-in-class molecules from the Amyloid Beta Oligomer-Selective Enhanced Brain Delivery Portfolio.
The private placement was led by existing investor RA Capital Management, with participation from other investors, including ADAR1 Capital Management, Sands Capital, and a large investment management firm.
The company expects to receive gross proceeds from the offering of approximately $35.75 million, before deducting offering expenses, and plans to close the private placement on or about March 16, 2026.

Generated by AI

Sentiment

Of the messages about ABOS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	96.85% +10.71
Bearish	—	—	0% 0	3.15% -10.71

Bullish· Jan 27

$ABOS has tremendous potential for growth, backed by big Pharma and successful drug development, which could lead to a significant stock price increase.
A BTIG analyst has upgraded the price target to $7 with a potential upside of 236.54%, indicating a strong buy recommendation.
The stock has seen a 23% intraday surge following a price target hike to $7, suggesting a strong market reaction to positive news.

Bearish· Jul 19

$ABOS's price may drop below its 200-day moving average of $5.65, potentially exacerbated by dilution.
Market makers are allegedly artificially inflating the stock price, as there are no real buyers at the current level of $7.25.
The company's lack of revenue and single-pipeline product make it a high-risk investment, with some analysts predicting a price drop to under $5 in the near future.

Generated by AI

Topics

Of the messages about ABOS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	100%	88.61%
Analysts	—	—	0%	3.16%
Controversies	—	—	0%	0%
Earnings	—	—	0%	0%
Macro	—	—	0%	0%
Technical Analysis	—	—	0%	8.23%

Analysts· Jul 26

Credit Suisse initiated coverage on Acumen Pharmaceuticals ($ABOS) with an Outperform rating and a price target of $26.
BofA Securities initiated coverage on Acumen Pharmaceuticals ($ABOS) with a Neutral rating and a price target of $20.
UBS initiated coverage on Acumen Pharmaceuticals ($ABOS) with a Buy rating and a price target of $27.

Announcements· Jul 17

Acumen Pharmaceuticals ($ABOS) announced positive topline results for its early Alzheimer's disease treatment, ACU193, in a Phase 1 clinical trial.
The company plans to hold a conference call to discuss the results and has proposed a public offering of common stock to raise $100 million.
The treatment, ACU193, met its primary endpoint in the Phase 1 trial, showing a significant decrease in amyloid plaque load, and several top Wall Street analysts have upgraded their rating to strong buy.

Technical Analysis· Sep 28

A technical analysis of $ABOS indicates a negative divergence on the chart, with higher highs and lower lows, suggesting a sign to exit the trade and take profit.
The stock's support levels are near $6.54, $7.19, and $7.83, while resistance levels are near $8.63, $9.11, and $9.69, with bulls still in control.
A potential breakout is indicated if $ABOS breaks above $9.50 with strength in the next 5-10 minutes, with a possible target of $11-12.

Generated by AI

Community

Of the messages about ABOS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	100%	80.43%	36.94%
Newcomers	0%	0%	19.57%	63.06%

Regulars· Jul 17

Acumen Pharmaceuticals announced positive topline results from a Phase 1 study of ACU193 for early Alzheimer's disease, with a "rapid" mean decrease in amyloid plaque load at 60 milligrams.
The company's shares climbed more than 37% in premarket trading, with some analysts noting a "nice ride" despite early data being low.
Acumen Pharmaceuticals will hold a conference call to discuss the positive results from the Phase 1 study, with details expected to be shared during the call.

Newcomers· Jan 27

The newcomer is excited about the rapid increase in Acumen Pharmaceuticals' stock price, which rose 52% yesterday, but is unsure of the reason behind it, as the company is set to announce 2nd stage results for its Alzheimer's treatment ACU193 on December 26th.
The newcomer is comparing Acumen Pharmaceuticals to Mindwalk, a biotech company that developed a rapid prime immunization method and its underlying antibodies, and is speculating on the potential success of Mindwalk's 2nd stage results.
The newcomer is tracking the stock price of Acumen Pharmaceuticals, which rose 20% after-hours, and is attributing the spike to flow/volatility-driven momentum, without any clear fresh PR headline attached.

Generated by AI

Acumen Pharmaceuticals

Social

Mar 16

Bullish· Jan 27

Bearish· Jul 19

Analysts· Jul 26

Announcements· Jul 17

Technical Analysis· Sep 28

Regulars· Jul 17

Newcomers· Jan 27

Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery

Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?

All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy

Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer’s Association International Conference

Also Discussed

Acumen Pharmaceuticals, Inc.

Company Information

Location

Aptar Pharma and Massachusetts General Hospital Collaborate on Platform to Establish Predictive, Data-Driven Model for Advancing Nose-to-Brain Drug Delivery

Are Medical Stocks Lagging Acumen Pharmaceuticals (ABOS) This Year?

All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy

Aptorum Group and DiamiR Biosciences Announce Three Presentations at 2026 Alzheimer’s Association International Conference

Also Discussed

Social

Mar 16

Bullish· Jan 27

Bearish· Jul 19

Analysts· Jul 26

Announcements· Jul 17

Technical Analysis· Sep 28

Regulars· Jul 17

Newcomers· Jan 27